Biologic therapy may be considered for selected autoimmune and inflammatory conditions that contribute to joint, spine, tendon, or systemic pain.
Learn how Dr. Aranguren explains biologic therapies, how they can help treat chronic pain and inflammatory conditions, and which patients may benefit from these advanced treatment options.
Our team organizes conditions and treatments into related zones of expertise to make it easier to explore the care paths most relevant to your symptoms and goals.
Use the zone tags above to browse dedicated pages for each focus area, including services, providers, and what to expect during treatment.
If you’re dealing with autoimmune or inflammatory conditions and still feeling stuck in cycles of pain, swelling, stiffness, or fatigue, you may have heard your doctor mention something called biologics.
Biologics are advanced medications designed to target very specific parts of the immune system that drive inflammation.
Unlike traditional medications that suppress the immune system more broadly, biologics work in a more targeted way by blocking inflammatory signals involved in conditions like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, and other autoimmune disorders.
When inflammation stays active for a long time, it can affect much more than just the joints. It can contribute to pain, fatigue, stiffness, nervous system sensitization, and long-term tissue damage.
The goal of biologic therapy is not just symptom relief. It’s helping reduce the inflammatory process itself so the body can function better and prevent ongoing damage over time.
These medications are usually given as injections or infusions, and treatment plans are highly individualized depending on the patient’s diagnosis, symptoms, lab work, and overall health picture.
My approach is always to look at the full clinical picture and understand whether ongoing inflammation may be driving the symptoms we’re seeing.
For many patients, biologics can be life-changing when used thoughtfully and monitored carefully.
If you’ve been dealing with chronic inflammatory symptoms, autoimmune disease, or persistent pain and stiffness that hasn’t improved enough with standard treatment, biologic therapy may be something worth discussing with your care team.
Biologics are targeted immune-modulating medications used for selected autoimmune and inflammatory conditions. They are not general pain medications. Instead, biologics may help reduce disease activity in conditions where inflammation contributes to pain, stiffness, swelling, enthesitis, sacroiliac pain, spine pain, psoriasis-related joint pain, or systemic symptoms.
At Manhattan Pain Medicine, biologic therapy NYC care is approached through diagnosis-first evaluation and coordination with rheumatology, dermatology, gastroenterology, or other specialists when appropriate. MPM helps identify inflammatory pain patterns, clarify overlapping pain generators, and integrate biologics into a broader care plan when clinically appropriate.
MPM specialists evaluate whether pain may be inflammatory, mechanical, neuropathic, autoimmune, hypermobility-related, centralized, or mixed. This matters because biologics may help selected inflammatory diseases, but they are not designed to treat every type of pain. A patient with rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, psoriasis with joint pain, enthesitis, or inflammatory SI joint pain may need biologic therapy coordination with rheumatology or another specialist.
MPM also considers whether pain may persist because of mechanical spine disease, nerve irritation, joint instability, small fiber neuropathy, or central sensitization, even when inflammatory disease is being treated.
Biologics work differently from NSAIDs, steroids, opioids, and other pain medications. They are designed to target specific immune cells, proteins, or inflammatory pathways involved in certain autoimmune and inflammatory diseases. Depending on the diagnosis, biologics may be given by injection or IV infusion and may be used when other treatments, such as NSAIDs or traditional DMARDs, are not enough or are not appropriate.
MPM does not present biologics as a standalone pain solution. The goal is to determine whether inflammation is a meaningful driver of symptoms and whether biologic therapy should be coordinated as part of the broader medical plan. This is especially important for patients with rheumatoid arthritis, psoriatic arthritis, psoriasis, seronegative spondyloarthropathy, enthesitis, sacroiliac pain, inflammatory spine pain, lupus, Sjogren’s, vasculitis, undifferentiated connective tissue disease, MCAS, gout, or overlapping chronic pain symptoms. Biologics may reduce inflammatory activity for selected patients, but pain may still require additional evaluation and care.
Biologic therapy fits within MPM’s Autoimmune and Inflammatory Zone of Expertise. Many patients with autoimmune or inflammatory disease experience pain from more than one source. Inflammation may affect joints, tendons, entheses, skin, spine, SI joints, or systemic function. At the same time, patients may also have neuropathic pain, small fiber neuropathy, mechanical spine pain, hypermobility-related pain, or centralized pain.
MPM helps evaluate these overlapping patterns so biologic therapy is not treated as the entire answer. When biologics are appropriate, they are coordinated with rheumatology, dermatology, gastroenterology, or another specialist. When pain persists despite biologic treatment, MPM helps evaluate whether additional pain generators need to be addressed through medication management, procedures, infusions, rehabilitation, or other care.
During evaluation, MPM reviews the patient’s diagnosis, symptoms, inflammatory pain features, medication history, prior DMARD or biologic use, labs, imaging, infection history, vaccine status, and specialist involvement. Patients may be asked about morning stiffness, swelling, flares, psoriasis, tendon or enthesis pain, SI joint pain, spine symptoms, fatigue, neuropathic symptoms, and treatment response.
If biologics may be appropriate, MPM may coordinate with rheumatology, dermatology, gastroenterology, or another clinician for medication selection and monitoring. Biologics may require screening for tuberculosis, hepatitis, infection risk, vaccine status, pregnancy considerations, malignancy history, demyelinating disease history, heart failure risk for some agents, and lab monitoring. Some biologics are injected, while others are given by infusion. The plan depends on the diagnosis, medication, safety profile, and care team.
I cannot say enough good things about Manhattan Pain Medicine. From the moment I walked in, I felt truly cared for and taken seriously. Dr. Nino Mikaberidze, Director of Rheumatology, is exceptional — knowledgeable, compassionate, and incredibly thorough. She takes the time to listen, explains every...
The best care I've received as a chronic pain patient. I traveled from out of state to visit Manhattan Pain Medicine because I could not find knowledgeable doctors in my hometown for my hypermobility, and Ehlers-Danlos syndrome symptoms and comorbidities. Let me tell you, it was worth every travel e...
I was injured in a bicycle accident over 8 years ago. I’ve suffered throughout the years since my accident with nothing seeming to work. PT, Yoga, lifestyle changes, NOTHNG! I finally made an appointment with Dr Kane and I’m feeling an improvement in my life. I no longer stay up all night in pain, a...
One of the best experiences, if not the best, I have ever had at the doctor’s office. From the front desk to the nurses to the PA assisting the doctor this was a great experience. Dr.Nino actually listened to me and came up with a game plan. Would recommend this practice to as many people as I could...
I have very unique & severe nerve pain from CRPS which has no known specific cure. Dr. Siefferman has a huge tool box, far greater than the other 23 Drs. I have seen. He saved me from jumping off a bridge and continues to help me with both treatments and advice. Dr. S. is in a different league!
After two years of searching and feeling lost and let down, I finally found real help at Manhattan Pain Medicine. With Dr. Siefferman, Adam Rosenberg, Dr. Mikaberidze, and the whole team, I feel heard, supported and understood. Every symptom is being considered and I’m finally getting answers with m...
Why is Dr Dr. Tayyaba Ahmed one of the top pevic Floor specialists - 1- She wants to know a full history of what led the patient to get to this point. 2 - She listens intensley to the patient 3- She does not rush you 4- Extremely skilled at giving pelvic floor injections 5- I thank my luck stars she...
The staff was friendly and helpful. Dr. Siefferman was thoughtful, listened, asked questions and proposed simple safe ways to come to further conclusions regarding my pain and discomfort. The office staff including Dr. Siefferman is responsive even after the initial in-person visit. Very pleased.
Dr. Siefferman is a brilliant provider. While my pain is still a work in progress, Dr Siefferman always gives me options and explains his reasoning behind things. He listens to my feedback and concerns. I never feel rushed; and am grateful he works to meet me where I am. I highly recommend him.
What a great find! They listen to me, I listen to them and the diagnosis is made and a plan developed to develop an approach to treat all of my chronic pain. I wish I could have discovered this type of treatment sooner. This doctor and group give me hope.
Biologics are targeted medications that affect specific parts of the immune system involved in inflammation. They may be used for selected autoimmune and inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, psoriasis, spondyloarthritis, ankylosing spondylitis, and other immune-mediated diseases when clinically appropriate. Biologics are not general pain medications. At MPM, biologic therapy is considered within a diagnosis-first care plan and is often coordinated with rheumatology, dermatology, gastroenterology, or another specialist.
Biologics are often considered a type of disease-modifying treatment, but they are different from traditional DMARDs. Traditional DMARDs and biologic DMARDs may both be used to reduce inflammatory disease activity, but they work in different ways and have different safety considerations. The right medication depends on the diagnosis, disease activity, prior treatment response, risks, and specialist guidance. MPM may coordinate biologic or DMARD-related care when inflammatory disease is contributing to pain.
Regular pain medications may target pain signals, inflammation, muscle spasm, or nerve sensitivity. Biologics target immune pathways involved in specific inflammatory diseases. They are not used simply because a patient has pain. They may be considered when an autoimmune or inflammatory condition is driving symptoms such as joint swelling, stiffness, enthesitis, psoriasis-related joint pain, inflammatory spine pain, or SI joint pain. MPM evaluates whether pain appears inflammatory, mechanical, neuropathic, centralized, or mixed before coordinating care.
Biologics may be used for selected autoimmune or inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, axial spondyloarthritis, inflammatory bowel disease-related arthritis, and other immune-mediated diseases depending on the medication and clinical situation. Some conditions, such as lupus, Sjogren’s, vasculitis, or undifferentiated connective tissue disease, require careful specialist evaluation because treatment options vary. MPM helps recognize inflammatory pain patterns and coordinate with appropriate specialists.
Biologics may help selected patients with rheumatoid arthritis by reducing inflammatory disease activity, which may reduce joint pain, swelling, stiffness, and functional limitation. They do not cure rheumatoid arthritis and may not resolve all pain, especially if there is mechanical joint damage, nerve pain, central sensitization, or another pain generator. MPM may coordinate with rheumatology to help determine whether persistent pain is inflammatory, structural, neuropathic, or mixed.
Biologics may help selected patients with psoriatic arthritis or psoriasis-related inflammatory symptoms by targeting immune pathways involved in skin and joint inflammation. They may be considered when psoriasis is associated with joint pain, swelling, stiffness, enthesitis, dactylitis, or spine symptoms. Pain may still have other contributors, including mechanical joint disease, tendon pain, nerve irritation, or central sensitization. MPM evaluates pain patterns and coordinates with dermatology or rheumatology when biologic therapy may be relevant.
Biologics may be considered for selected patients with axial spondyloarthritis, ankylosing spondylitis, psoriatic arthritis, or inflammatory sacroiliac pain when symptoms and specialist evaluation support that diagnosis. SI joint pain can also be mechanical, hypermobility-related, degenerative, traumatic, or referred from the spine. MPM evaluates whether the pain pattern suggests inflammation or another pain generator. Biologic therapy should be coordinated with rheumatology when inflammatory spine or SI joint disease is suspected.
Biologics may help selected patients with inflammatory enthesitis, which involves inflammation where tendons or ligaments attach to bone. Enthesitis can occur in psoriatic arthritis and spondyloarthritis. However, tendon or attachment-site pain can also come from overuse, tendinopathy, mechanical strain, hypermobility, or injury. MPM evaluates whether symptoms appear inflammatory or mechanical before recommending next steps. If inflammatory enthesitis is suspected, rheumatology coordination may be needed.
Biologics may be given by injection or IV infusion, depending on the medication and condition being treated. Some are self-injected at home under medical guidance, while others are administered in an infusion setting. The choice depends on diagnosis, medication type, safety profile, insurance authorization, monitoring needs, and specialist recommendation. MPM may coordinate around biologic injections or biologic infusions when they are part of a broader autoimmune and inflammatory pain care plan.
Testing depends on the medication and patient history, but biologics often require screening before treatment begins. This may include tuberculosis screening, hepatitis screening, infection review, vaccine status review, lab work, medication interaction review, pregnancy considerations, and assessment of other risks such as malignancy history, demyelinating disease, or heart failure risk for certain agents. MPM coordinates with treating specialists to support safe biologic therapy planning when inflammatory pain is part of the patient’s condition.
Risks vary by medication, but biologics may increase infection risk and can cause injection-site reactions, infusion reactions, allergic reactions, lab abnormalities, fatigue, rash, or medication-specific adverse effects. Some biologics require caution in patients with certain infection risks, malignancy history, demyelinating disease, heart failure risk, pregnancy considerations, or medication interactions. MPM does not treat biologics as routine pain medications. Safety review and specialist coordination are important before and during treatment.
Yes, many biologics can increase infection risk because they affect immune system activity. Patients may need screening for infections such as tuberculosis or hepatitis before starting treatment. They may also need vaccine review, infection monitoring, and instructions about when to contact a clinician. Fever, worsening infection symptoms, shortness of breath, severe rash, or signs of serious illness should be evaluated promptly. MPM coordinates with specialists to help keep biologic therapy connected to safe, monitored care.
Yes, biologics may be combined with other pain treatments when clinically appropriate. A patient with inflammatory arthritis may also have mechanical spine pain, tendinopathy, neuropathic pain, SI joint dysfunction, or central sensitization. Treatment may include medication management, infusions, diagnostic ultrasound, injections, physical rehabilitation, pain psychology, or other specialist care. MPM helps determine whether persistent pain is still inflammatory or whether another pain generator should be evaluated and treated.
MPM’s role is to evaluate pain patterns, identify signs of inflammatory disease, clarify overlapping pain generators, and coordinate with rheumatology when biologic therapy may be relevant. Rheumatology often manages the autoimmune diagnosis, medication selection, safety screening, and disease activity monitoring. MPM may support the pain care plan by evaluating mechanical, neuropathic, pelvic, spine, or centralized pain contributors that may persist even when inflammatory disease is being treated.
Before care begins, our team helps patients understand the practical side of treatment, including insurance verification, out-of-network benefits, cost-share estimates, self-pay options, and billing questions. We believe patients should have as much clarity as possible before moving forward.
Biologic therapy is a targeted medication strategy used for selected autoimmune and inflammatory diseases. Biologics are not general pain medications. They are designed to affect specific immune pathways that contribute to inflammation. When inflammation is driving pain, stiffness, swelling, enthesitis, psoriasis-related joint pain, sacroiliac pain, or inflammatory spine pain, biologics may be part of the treatment plan.
At Manhattan Pain Medicine (MPM), biologic therapy NYC care is approached through diagnosis-first evaluation and specialist coordination. The goal is to determine whether pain is truly inflammatory, whether biologics may be relevant, and whether other pain generators also need to be addressed.
Pain medications may reduce pain signals, inflammation, muscle spasm, nerve sensitivity, or symptom burden. Biologics are different. They are disease-directed medications used for specific autoimmune or inflammatory conditions. Depending on the diagnosis, they may target immune proteins or cells involved in inflammatory disease activity.
Biologics may be used for selected patients with rheumatoid arthritis, psoriatic arthritis, psoriasis, axial spondyloarthritis, ankylosing spondylitis, inflammatory bowel disease-related arthritis, or other immune-mediated conditions. Some may be given by injection, while others are given by IV infusion.
DMARDs and biologics are often discussed together because both may be used to modify inflammatory disease activity. Traditional DMARDs and biologic DMARDs work differently, and the choice depends on diagnosis, disease severity, prior treatment response, safety profile, and specialist recommendation. Some patients may be considered for biologics when NSAIDs, steroids, or DMARDs are not enough or are not appropriate.
MPM does not replace rheumatology or dermatology management. Instead, MPM helps evaluate how inflammatory disease may be contributing to pain and how biologic therapy fits with the broader pain plan. This may include reviewing whether symptoms suggest active inflammation, structural damage, nerve pain, spine disease, hypermobility, or central sensitization.
Biologics may be relevant when pain is linked to inflammatory arthritis, psoriasis with joint pain, psoriatic arthritis, enthesitis, sacroiliitis, or inflammatory spine pain. For example, a patient with psoriasis and joint stiffness may need evaluation for psoriatic arthritis. A patient with SI joint pain and prolonged morning stiffness may need evaluation for axial spondyloarthritis. A patient with tendon insertion pain may need assessment for inflammatory enthesitis.
However, these symptoms are not always inflammatory. SI joint pain can be mechanical. Spine pain can be degenerative. Tendon pain can be overuse-related. Joint pain can be caused by osteoarthritis, gout, injury, nerve irritation, or hypermobility. MPM evaluates these possibilities so biologics are considered only when the clinical picture supports inflammatory disease.
Some patients still have pain even after inflammatory disease is controlled. This does not mean the pain is not real. It may mean that another pain generator is present. Persistent symptoms may come from joint damage, tendinopathy, nerve irritation, small fiber neuropathy, spine disease, sacroiliac joint dysfunction, hypermobility, central pain sensitization, or deconditioning.
MPM helps evaluate these overlapping contributors. A patient may need diagnostic ultrasound, imaging review, medication management, targeted injections, infusions, rehabilitation, or additional specialist coordination. Biologics may reduce inflammatory disease activity, but they may not resolve pain from mechanical, neuropathic, hypermobility-related, or centralized sources.
Biologics require careful safety review. Depending on the medication, patients may need screening for tuberculosis, hepatitis, infection risk, vaccine status, pregnancy considerations, malignancy history, demyelinating disease history, heart failure risk, lab monitoring, and medication interactions. Infusion-based biologics may also require monitoring for infusion reactions.
Patients should report fever, signs of infection, shortness of breath, chest pain, severe allergic reaction, infusion reaction, new neurological symptoms, severe abdominal pain, black or bloody stool, severe rash, yellowing of the skin or eyes, rapidly worsening weakness, or rapidly worsening symptoms.
Biologic therapy is usually managed with rheumatology, dermatology, gastroenterology, or another specialist depending on the underlying disease. MPM’s role is to connect inflammatory disease treatment with pain generator evaluation and coordinated care.
For selected patients, biologics may be an important part of autoimmune and inflammatory pain care. MPM helps determine whether inflammation is likely contributing to symptoms, whether additional pain sources need to be treated, and how biologic therapy should fit safely within the patient’s broader care plan.
